James Larocque is an Endocrinology/Metabolic physician affiliated with Chesapeake Public Schools. OpenAlex indexes 18 publications with 541 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3205 Churchland Blvd
Chesapeake, VA 233215205
Telephone
757-484-7822Registry record last updated 20 Jun 2014.
Industry payments
53 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Corcept TherapeuticsProgram year202518 payments
- KYOWA KIRIN, INC.Program year20255 payments
- Mannkind CorporationProgram year202514 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
60.8%Insulin Analog20.9%Lantus Solostar36%Humalog Kwikpen U-10012%Novolog Flexpen9%Insulin Lispro Kwikpen U-1007%Basaglar Kwikpen U-1007%Novolog5%Humalog4%Toujeo Max Solostar3%Toujeo Solostar3%Insulin Lispro3%Tresiba Flextouch U-1003%Lantus3%Insulin Aspart Flexpen1%Fiasp Flextouch1%Levemir Flexpen1%Tresiba Flextouch U-2001%Soliqua 100-331%Fiasp1%Part D<11 patientsGLP-1 receptor agonist9.9%Ozempic43%Trulicity42%Mounjaro8%Victoza 3-Pak3%Rybelsus3%Liraglutide2%Part D<11 patients+ 12 more classes in this area
Hormonal (systemic)
24.2%l-Thyroxine15.7%Levothyroxine Sodium79%Synthroid22%Part D≥256 patientsl-Triiodothyronine3.4%Liothyronine Sodium100%Part D≥79 patients+ 5 more classes in this area
Cardiovascular
7.3%Statin2.2%Atorvastatin Calcium39%Simvastatin39%Rosuvastatin Calcium14%Pravastatin Sodium8%Part D<11 patientsAldosterone antagonist (MRA)1.5%Spironolactone100%Part D≥31 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Artemis inhibition as a therapeutic strategy for acute lymphoblastic leukemia
Frontiers in Cell and Developmental Biology
2023 - The relation of abuse to physical and psychological health in adults with developmental disabilities
Disability and health journal
2019 - The Role of Gender in Violence Experienced by Adults With Developmental Disabilities
Journal of Interpersonal Violence
2015
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”